-transparent.png){kind=logo}
Deferiprone is an oral chelating agent that has been recently shown to reduce cardiac siderosis, but is also known to be associated with serious side effects like agranulocytosis which can be fatal. This report is a single centre experience of 5 cases with severe agranulocytosis in amongst 144 patients (3.47%) of thalassemia major on combined chelation therapy with subcutaneous desferrioxamine and oral deferiprone which is much higher than the previous reports.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
August 1995,
Indian pediatrics,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
August 2010,
Pediatric hematology and oncology,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
June 2009,
JPMA. The Journal of the Pakistan Medical Association,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
April 1995,
The New England journal of medicine,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
December 1998,
The New England journal of medicine,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
December 1998,
The New England journal of medicine,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
December 1998,
The New England journal of medicine,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
December 1998,
The New England journal of medicine,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
December 1998,
The New England journal of medicine,
Yasser Wali, and
Azza Al Shidhani, and
Shahina Daar
December 1998,
The New England journal of medicine,
